To learn more visit http://www.YouAndMelanoma.comRekha Chaudhary, MD, a hematologist and oncologist who specializes in the treatment of melanoma at the University of Cincinnati, explains some of the important criteria that make a melanoma patient eligible for tumor infiltrating lymphocyte (TIL) therapy. Patients need a tumor large enough and accessible enough to biopsy for TIL therapy. They also need to be healthy enough to undergo the chemotherapy, or lymphodepletion, as well as the IL-2 infusions to receive the TIL therapy.
LaQuisa Hill, MD, Texas Children’s Hospital, Houston Methodist Hospital, Houston, TX, discusses the optimal time for patients with non-Hodgkin lymphoma (NHL) to receive chimeric antigen receptor (CAR) T-cell therapy. For patients with T-cell lymphoma, CAR-T cell therapy is recommended if they failed first-line therapy and earlier referrals can improve the quality of the product, as well as decrease waiting times for patients who need treatment. Cells can additionally be collected and frozen for later use, which reduces the need for cells that have been previously exposed to lymphodepleting agents. This interview took place at the 63rd ASH Annual Meeting and Exposition congress in Atlanta, GA.
Michael Bishop, MD, University of Chicago, Chicago, IL, discusses results from the Phase III BELINDA trial (NCT03570892), which assessed tisagenlecleucel (tisa-cel), a chimeric antigen receptor (CAR) T-cell therapy, in patients with aggressive B-cell non-Hodgkin lymphoma. The primary endpoint, which was event-free survival, was not met, and tisa-cel was not superior to the current standard of care. Dr Bishop highlights the time taken for the therapy to be administered, bridging therapy, and the dosage of lymphodepleting chemotherapy to be factors affecting the trial results. This interview took place at the 63rd ASH Annual Meeting and Exposition congress in Atlanta, GA.